Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
Portfolio Pulse from
Palisade Bio announced preliminary data from its Phase 1 clinical study of PALI-2108, showing it is safe and well-tolerated in treating moderate-to-severe ulcerative colitis. The study reported no treatment-related adverse events in the first three single ascending dose cohorts.
December 03, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio's preliminary Phase 1 study results for PALI-2108 indicate safety and tolerability in treating ulcerative colitis, with no adverse events in initial cohorts.
The announcement of positive safety data from the Phase 1 study of PALI-2108 is likely to boost investor confidence in Palisade Bio, as it suggests the drug is progressing well in its development. The absence of adverse events is a positive indicator for future trial phases, potentially leading to increased stock interest and price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100